Hormonal
Tirzepatide (5-15 mg weekly) produces superior weight loss (10.7-20.9%) compared to placebo in adults with obesity (BMI ≥30 or ≥27 with comorbidities) via dual GIP/GLP-1 receptor agonism.
Tirzepatide is a once-weekly injection that significantly reduces body weight (up to 20%+) in obese adults. It works by mimicking gut hormones to suppress appetite and slow digestion. Start with the lowest dose and increase gradually to minimize stomach upset. Combine with a 500-calorie daily deficit and 150 minutes of weekly exercise for best results.
Tirzepatide demonstrated significant weight reduction across studies: SURMOUNT-1 (15.0%, 19.5%, 20.9% weight loss for 5, 10, 15 mg doses respectively)... Adverse effects were mostly gastrointestinal, with nausea, diarrhea, and vomiting being the most common, leading to a discontinuation rate of 4.6%.
Why this rating
Based on multiple phase 2 and 3 randomized, placebo-controlled trials.
Source
TIRZEPATIDE IN OBESITY MANAGEMENT: EFFICACY AND SAFETY - INSIGHTS FROM RECENT CLINICAL TRIALS
Jakub Cecot et al. · Archiv Euromedica · 2024
DOI 10.35630/2024/14/4.412
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →